

## **PSILOCYBIN PRODUCT AND END OF SESSION FORM**

**Instructions:** This form has three parts. Service Centers complete the “Sale and Transfer of Psilocybin Products” to document the dose of psilocybin products sold and transferred to clients, including any secondary doses. Service Centers will also work with facilitators after the administration session to complete documentation of products that were transferred to clients but not consumed. The client consents to receive products by completing the “Client Acknowledgement” prior to beginning an administration session. Both a facilitator and the client sign the “Client Release from Administration Session” at the conclusion of the administration session to document a client’s release from an administration session.

This form must be stored in the client file and will not be submitted to Oregon Psilocybin Services unless requested. For more information on psilocybin product potency, facilitators are encouraged to share the [Psilocybin Product Potency Information Document](#) with clients prior to an administration session. The information document may support client decisions regarding the product types and dosage that align with their intentions for the administration session.

Client Name: \_\_\_\_\_

Facilitator Name(s): \_\_\_\_\_

Service Center Name: \_\_\_\_\_

Date of Administration Session: \_\_\_\_\_

### 1) Sale and Transfer of Psilocybin Products

This section documents primary and secondary doses of psilocybin products sold and transferred to clients for consumption during an administration session.

Please complete this section for every client that participates in an administration session. For clients who do not purchase secondary doses please write “N/A” for the secondary dose description.

#### Primary Doses

Description of psilocybin products to be transferred to the client (product type, dosage, quantity, UID, and price) as a primary dose:

Did client consume the entire amount of product transferred?

Yes       No

If no, why not? \_\_\_\_\_

If no, please describe what products were wasted (product type, dosage, quantity, UID): \_\_\_\_\_

### Secondary Doses

A service center may permit a client to consume a secondary dose of psilocybin product during an administration session. If a client consumes a secondary dose, the total amount of psilocybin analyte consumed must not exceed 50 mg.

The minimum duration of an administration session is dependent on the total amount of psilocybin a client consumes, including any secondary doses. The minimum duration is calculated from the time that the initial dose of psilocybin is consumed. After the minimum duration elapses, facilitators consult with client to determine whether continuing the administration session is necessary to ensure the client's safety or public safety.

Clients must purchase the secondary dose prior to beginning their administration session and store the secondary dose at a designated secured location within the service center. If clients would like to consume the secondary dose during their administration session, the licensee representative of the licensed service center may assist to retrieve the product. Clients must consume the secondary dose without assistance from the licensee representative or facilitator. If the secondary dose is not consumed, it must be returned unopened to the service center.

Clients who would like to purchase and consume secondary doses must provide written consent prior to beginning their administration session.

Description of psilocybin products the client plans to consume (product type, dosage, quantity, UID, and price) as a secondary dose, if applicable:

Did the client retrieve the secondary dose during their administration session?

Yes     No

Did the client consume the entire secondary dose?     Yes     No

If no, why not? \_\_\_\_\_

If no, please describe what products were wasted or returned to inventory (product type, dosage, quantity, UID, and price refunded to client):

\_\_\_\_\_

## 2) Client Acknowledgment

By signing below, I agree to receive the primary and secondary doses of psilocybin products described above during my administration session.

Client

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

### 3) Client Release from Administration Session

OPS rules state that facilitators must require a client to sign a release form that states that the client agrees to end their administration session. Facilitators are required to attempt to contact clients within 72 hours of the conclusion of an administration session to offer the client information on integration sessions and other services. Facilitators must also document any post session reactions using the [Client Adverse Reaction Form](#). To end an administration session, the following criteria must be met:

- The required minimum duration of the administration session at the licensed service center has been reached based on the total amount of psilocybin analyte consumed including any secondary dose
- The client is comfortable being released from the administration session.
- The facilitator is comfortable releasing the client from the session.
- The client agrees to follow the terms of their transportation plan.

Date and time administration session concluded:

\_\_\_\_\_

I agree to conclude my administration session at the time listed above.

I agree to follow the terms of my transportation plan.

Client Name: \_\_\_\_\_

Client Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Time: \_\_\_\_\_

I am comfortable releasing the client from the administration session.

Facilitator Name: \_\_\_\_\_

Facilitator Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Time: \_\_\_\_\_